Close Menu

Qlucore's Omics Explorer

Feb 11, 2015

Qlucore has released Omics Explorer 3.1, the latest version of its advanced data analysis software. This release includes a well-defined open interface to R that gives users access to a broader range of statistical tests and a more flexible colour scale.

More Like This

Aug 04, 2020

Horizon Discovery Single Cell RNAseq-Linked CRISPR Screening Service

Horizon Discovery has added single cell RNAseq-linked pooled CRISPR screening to its CRISPR screening services portfolio. Coupling pooled CRISPR screening to single cell RNAseq allows the impact of CRISPR-based gene modification to be examined on a global transcriptomic scale at single cell resolution. The platform offers high-quality screening data and biological insight to address gaps in target identification and validation by integrating the effect of gene editing with complex gene expression mapping, the company said. 

Aug 04, 2020

Adaptive Biotechnologies immunoSeq T-Map COVID service

Adaptive Biotechnologies has launched the immunoSeq T-Map COVID, a proprietary research product and data analysis service to measure the T cell immune response to vaccines in development and track the persistence of that response over time.

The product leverages data from over 1,000 patients to provide researchers with a quantitative map of T cell receptors and SARS-CoV-2 antigens that elicit an immune response. These data will be available through Adaptive's cloud-based immunoSeq Analyzer and is powered by ImmuneCode, an open database developed in partnership with Microsoft.

Aug 03, 2020

Cytek Biosciences cFluor Reagents

Flow cytometry firm Cytek Biosciences announced the launch cFluor reagents, short for "Cytek Fluorochrome," that are validated on the firm's Aurora and Northern Lights full spectrum cell analysis systems. The first batch of reagents includes cFluor YG584, cFluor B548, and cFluor R710 and allows users to reveal more from the full spectrum panel with a new option excitable by the yellow-green, blue, and red lasers respectively. Other dyes are coming soon, the firm said. 

Aug 03, 2020

Personalis NeXT Liquid Biopsy

Personalis has launched NeXT Liquid Biopsy, its plannd exome-scale blood-based tumor-profiling assay for advanced-stage solid tumor cancer patients. According to the company, the test monitors over twenty times more genes than most targeted liquid biopsy panels that have entered the market. Personalis believes its more comprehensive option can help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid the development of next-generation cancer therapies. 
Jul 31, 2020

Myriad Genetics Amplify for Fetal Cell-Free DNA Sequencing

Myriad Genetics has launched Amplify, which sequences the fetal cell-free DNA fragments circulating in a mother's blood and increases the fetal fraction in a sample for non-invasive prenatal screening. The company is hoping that the technology will improve the performance of its Prequel NIPS test. The analytical validation of Amplify involved samples from more than 1,000 women and showed that the fetal fraction was 2.3 times greater on average compared to standard NIPS. The improvement reduces false positive and false negative results, including for common aneuploidies, expanded aneuploidies, microdeletions, and a baby's sex, Myriad noted. The company also said that the technology will reduce the number of sampels that fail to produce a result due to low fetal fraction and deliver results to 99.9 percent of patients. 

Jul 30, 2020

Diagenode, Alithea Genomics Mercurius Bulk RNA Sequencing Services

Diagenode, a firm providing epigenomics services and library prep products, has announced a new bulk 3' mRNA sequencing service, developed in collaboration with Alithea Genomics.

The service incorporates Alithea's Mercurius barcoding for high-throughput transcriptomics and can be scaled for large study cohorts.

Jul 29, 2020

HTG Molecular Diagnostics HTG EdgeSeq Pan B-Cell Lymphoma Panel

HTG Molecular Diagnostics has launched its HTG EdgeSeq Pan B-Cell Lymphoma Panel, which the firm said is designed to provide molecular characteriation of aggressive, indolent, and rare lymphomas. The research-use-only panel enables investigators to measure the expression of about 300 genes linked to the lymphoma transcriptome. The panel is available in kit form or as a service at HTG's VERI/O laboratory. 

Jul 28, 2020

Twist Bioscience RUO SARS-CoV-2 Antibody Panels

Twist Bioscience is offering two new SARS-CoV-2 antibody panels for research use only.

The Twist anti-SARS-CoV-2 S1 antibody panel includes 32s human antibodies that bind with picomolar to nanomolar affinity to the S1 spike protein of the virus that causes COVID-19. The Human anti-ACE2 panel includes 48 antibodies that bind to the extracellular domain of the ACE2 receptor on human cells, the protein that facilitates entry of the coronavirus into cells.

All antibodies are cloned into human antibody backbones to generate VHH Fc, IgG1, or IgG2 antibodies. Individual antibodies within the panel can be licensed for further therapeutic or diagnostic development.

Jul 22, 2020

Twist Bioscience Synthetic Controls for Respiratory Viruses

Twist Bioscience has added 16 new synthetic controls for common respiratory viruses with symptoms similar to COVID-19, including influenza H1N1, influenza H32N, influenza B, rhinovirus, enterovirus, and several human coronaviruses including a prevalent mutated strain of SARS-CoV-2 (D614G.)

Applications for the products include environmental testing, assay development and verification, and diagnostic test validation.

Twist's controls are designed based on specific viral variants, cover the full viral genomes and are sequence-verified. Controls for alternative viral variants are available as custom products. The firm said RNA synthetic controls should be delivered within two weeks of ordering.

Jul 20, 2020

Bio-Techne miRNAscope Assay

Bio-Techne announced the expansion of its RNAscope platform in the form of the miRNAscope Assay. The miRNAscope Assay extends the firm's RNAscope technology to enable the in situ detection of short nucleic acid targets between 17 and 50 nucleotides, which includes microRNAs and short synthetic oligonucleotide therapeutics such as small interfering RNAs and antisense oligonucleotides.

Jul 17, 2020

Cepheid Xpert MTB/XDR

Cepheid has launched an assay to detect extensively drug-resistant tuberculosis. The CE-IVD marked Xpert MTB/XDR test uses new 10-color technology and runs on recalibrated GeneXpert instruments. It can be used to rapidly detect resistance to isoniazid, ethionamide, fluoroquinolones, amikacin, kanamycin, and capreomycin directly from patient specimens.

Jul 17, 2020

BioMérieux BioFire Mycoplasma

BioMérieux has launched BioFire Mycoplasma, an assay to detect mycoplasma bacteria in pharmaceutical products. The test is now available in the US, and will be launched in some countries in Europe and the Asia-Pacific region in the coming months.

Jul 16, 2020

RareCyte Orion Instrument

RareCyte has launched a new spatial biology analysis platform called Orion. The system is based on a patented and proprietary microscopy technology that allows comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment at what the company claims are much faster speeds and with more efficiency than existing technologies.

The platform includes the Orion instrument and associated TissuePlex reagents. The instrument images an entire pathology slide at high speed and high resolution in 21 fluorescence channels. Companion TissuePlex panels are shipped as customizable catalog labelling kits. Customers can also access the technology through RareCyte laboratory services and other specified programs.

Jul 15, 2020

Congenica Automation

Congenica has updated its clinical decision support platform by launching the Automated Classification of Known Variants product, Congenica Automation. This will provide automated classification as well as evidence and reporting of recurrent 'known' variants that customers observe in their rare disease cases. The new product aims to reduce interpretation and reporting time by 90 percent compared to the company's existing solution, so complex genomic data can be reported in as little as 5 minutes. For example, interpretation and reporting of 4,000 cases with recurrent pathogenic or likely pathogenic variants could be completed in 5 to 8 minutes for each case. Users of the new product can also create their own customized curated variant list to be used for the automated process.

Jul 14, 2020

10x Genomics Chromium Single Cell Immune Profiling v2

10x Genomics has launched the Chromium Single Cell Immune Profiling v2 product. It extends the capabilities of the original version, offering up to 60 percent increased gene detection sensitivity. The product can be used to characterize adaptive and innate immune cell diversity; identify and characterize rare cell types and biomarkers; analyze tissue microenvironment, disease progression, and drug immune response; perform large-scale antibody and TCR discovery for novel antigens; characterize immune responses to infection by measuring clonal expansions and immune cell phenotypes; and study genes and pathways with predesigned gene expression panels.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.